Targeting apoptosis pathways in lung cancer

Pore, Milind; Hiltermann, T. Jeroen N.; Kruyt, Frank A.E.

doi:10.1016/j.canlet.2010.09.012

Cited by 81 publications

(84 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Spierings et al have found immunohistochemically low TRAIL expression in 9% of NSCLC samples and high TRAIL expression in 59% of NSCLC samples in 87 stage III NSCLC patients and that poorly differentiated tumor areas of NSCLC patients exhibit a strong staining pattern for TRAIL [4]. Luo et al indicated that the genetic polymorphisms and haplotypes of TRAIL gene correlated significantly with the NSCLC susceptibility in the group of Chinese patients [6].…”

Section: Discussionmentioning

confidence: 99%

“…They behave differently in terms of biologically and sensitivity to chemotherapy and radiotherapy [2,3]. NSCLC is responsible for 80–85% of lung cancer patients and is divided into squamous cell carcinoma, adenocarcinoma, and large cell carcinoma subtypes based on histological features [4]. Lung cancer frequency is depended on many factors such as smoking, passive smoking, occupational and environmental factors, genetic susceptibility, age, gender, and ethnicity [2].…”

Section: Introductionmentioning

confidence: 99%

“…T mutant allele frequency was found to be significantly higher in patients with NSCLC [6]. The expression of apoptosis-inducing ligands such as TRAIL has been suggested to play an important role in cell regulation and may provide an immunological advantage for tumor cells [4]. TRAIL have determined is expressed by 91% of patients with NSCLC in immunohistochemical-based studies [3,4].…”

Section: Introductionmentioning

confidence: 99%

“…The expression of apoptosis-inducing ligands such as TRAIL has been suggested to play an important role in cell regulation and may provide an immunological advantage for tumor cells [4]. TRAIL have determined is expressed by 91% of patients with NSCLC in immunohistochemical-based studies [3,4]. Spierings et al have determined immunohistochemically low TRAIL expression in 9% of NSCLC samples and high TRAIL expression in 59% of NSCLC samples in 87 stage III NSCLC patients [4].…”

Section: Introductionmentioning

confidence: 99%

“…TRAIL have determined is expressed by 91% of patients with NSCLC in immunohistochemical-based studies [3,4]. Spierings et al have determined immunohistochemically low TRAIL expression in 9% of NSCLC samples and high TRAIL expression in 59% of NSCLC samples in 87 stage III NSCLC patients [4]. As also stated in the article of Luo et al, in an immunohistochemical study performed in 60 NSCLC tissue, the positive staining rate of TRAIL protein was found to be significantly lower in the tumor tissue compared to the adjacent normal tissue [6].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Effect of trail C1595T variant and gene expression on the pathogenesis of non-small cell lung cancer

Erbasoglu

Horozoglu

Ercan

et al. 2018

Libyan Journal of Medicine

View full text Add to dashboard Cite

It is known that disorders in apoptosis function play an important role in the pathogenesis of many types of cancer, including lung cancer. Tumor necrosis factor related apoptosis inducing ligand (TRAIL), a type II transmembrane protein, is a death ligand capable of inducing apoptosis by activating distinctive death receptor. Our purpose in this study is to investigate the gene polymorphisms in TRAIL molecular pathway and TRAIL gene expression levels in non-small cell lung cancer (NSCLC) patients in terms of pathogenesis and prognosis of the disease. In this study, TRAIL C1595T polymorphism was genotyped using polymerase chain reaction-restriction fragment length polymorphism analysis in 158 patients with NSCLC and 98 healthy individuals. Surgically resected tissues were examined and classified histopathologically. In addition, TRAIL gene expression levels in tumor tissue and tumor surrounding tissue samples of 48 patients with NSCLC were determined using real-time polymerase chain reaction. TRAIL gene expression levels of NSCLC patients were detected significantly 28.8 fold decrease in the tumor tissue group compared to the control group (p=0.026). When patients were compared to tumor stage, expression of TRAIL gene in advanced tumor stage was found to be significantly 7.86 fold higher than early tumor stage [p=0.028]. No significant relationship was found between NSCLC predisposition and prognostic parameters of NSCLC with TRAIL genotypes, but the frequency of TRAIL gene 1595 CT genotype was observed to be lower in the patients compared to the other genotypes, and the difference was found to be very close to statistical significance (p=0.07). It can be suggested that TRAIL may play an important role in the development of NSCLC and may be an effective prognostic factor in tumor progression.: It is known that disorders in apoptosis function play an important role in the pathogenesis of many types of cancer, including lung cancer. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a type II transmembrane protein, is a death ligand capable of inducing apoptosis by activating distinctive death receptor. Our purpose in this study is to investigate the gene polymorphisms in TRAIL molecular pathway and TRAIL gene expression levels in non-small cell lung cancer (NSCLC) patients in terms of pathogenesis and prognosis of the disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Effect of trail C1595T variant and gene expression on the pathogenesis of non-small cell lung cancer

Erbasoglu

Horozoglu

Ercan

et al. 2018

Libyan Journal of Medicine

View full text Add to dashboard Cite

show abstract

A new series of benzoxazole‐based SIRT1 modulators for targeted therapy of non‐small‐cell lung cancer

Sever

Çiftçi

Altıntop

2020

Archiv der Pharmazie

View full text Add to dashboard Cite

In an attempt to identify potential anticancer agents for non‐small‐cell lung cancer (NSCLC) targeting sirtuin 1 (SIRT1), the synthesis of a new series of benzoxazoles (3a – i) was carried out through a facile and versatile synthetic route. The compounds were evaluated for their cytotoxic effects on A549 human lung adenocarcinoma and NIH/3T3 mouse embryonic fibroblast cells using the MTT assay. 2‐[(5‐Nitro‐1H‐benzimidazol‐2‐yl)thio]‐N‐(2‐methylbenzoxazol‐5‐yl)acetamide (3e) and 2‐[(5‐chloro‐1H‐benzimidazol‐2‐yl)thio]‐N‐(2‐methylbenzoxazol‐5‐yl)acetamide (3g) were the most potent and selective anticancer agents in this series against the A549 cell line, with IC50 values of 46.66 ± 11.54 and 55.00 ± 5.00 µM, respectively. The flow cytometry‐based apoptosis detection assay was performed to determine their effects on apoptosis in A549 cells. Both compounds induced apoptosis in a dose‐dependent manner. The effects of compounds 3e and 3g on SIRT1 activity were determined. On the basis of in vitro studies, it was observed that compound 3g caused a significant decrease in SIRT1 levels in a dose‐dependent manner, whereas compound 3e increased the SIRT1 levels. According to molecular docking studies, the substantial alteration in the type of action could be attributed to the difference between the interactions of compounds 3e and 3g with the same residues in the active site of SIRT1 (PDB code: 4IG9). On the basis of in silico ADME (absorption, distribution, metabolism, and excretion) studies, these compounds are predicted to possess favorable ADME profiles. According to the in vitro and in silico studies, compounds 3e and 3g, small‐molecule SIRT1 modulators, were identified as potential orally bioavailable anticancer agents for the targeted therapy of NSCLC.

show abstract

Evaluating Antibiofilm, Cytotoxic and Apoptotic Activities ofScutellaria brevibracteatasubsp.brevibracteataEssential Oil

Kart,

Günal,

Mutlu

et al. 2023

Chemistry & Biodiversity

View full text Add to dashboard Cite

Essential oils have many important biological properties, including antibacterial and antibiofilm activities. These unique properties make, essential oils good alternatives to synthetic chemical drugs, which have many side effects. In this study, we aimed to determine the chemical composition and biological activity of the essential oil obtained from Scutellaria brevibracteata subsp. brevibracteata. Specifically, its antibiofilm activity against Pseudomonas aeruginosa PAO1 and Staphylococcus aureus ATCC 29213 biofilms using XTT assay. Cytotoxic and apoptotic properties of the essential oil were investigated in human lung cancer cells (A540 and H1299) using MTT assay, Annexin V‐FITC and propidium iodide staining and q‐PCR. Thirty‐two different compounds were identified from the essential oil, of which elemol (20.42%), γ‐eudesmol (20.12%) and β‐eudesmol (14.85%) were the main components. The essential oil was more effective against P. aeruginosa PAO1 biofilm (79%) than S. aureus ATCC 29213 biofilm (27%). The specific activity of the essential oil against P. aeruginosa biofilm may be related to its high terpene contents. In addition, the essential oil showed high cytotoxic activity towards A549 (IC50 9.09 µg/ml) and H1299 (IC50 55.04 µg/ml) cell lines, inducing apoptosis in these cancer cells. These results demonstrate the antibiofilm and anticancer activities of S. brevibracteata subsp. brevibracteata essential oil.

show abstract

Targeting apoptosis pathways in lung cancer

Cited by 81 publications

References 97 publications

Effect of trail C1595T variant and gene expression on the pathogenesis of non-small cell lung cancer

Effect of trail C1595T variant and gene expression on the pathogenesis of non-small cell lung cancer

A new series of benzoxazole‐based SIRT1 modulators for targeted therapy of non‐small‐cell lung cancer

Evaluating Antibiofilm, Cytotoxic and Apoptotic Activities ofScutellaria brevibracteatasubsp.brevibracteataEssential Oil

Contact Info

Product

Resources

About